American Society of Hirudotherapy

Identification and Characterization of RK22, a Novel Antimicrobial Peptide from Hirudinaria manillensis against Methicillin Resistant Staphylococcus aureus

Lu X, Yang M, Zhou S, Yang S, Chen X, Khalid M, Wang K, Fang Y, Wang C, Lai R, Duan Z (2023) · International Journal of Molecular Sciences

Preclinical / molecular study: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Study record: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.

Study Profile

Model / material
bioinformatic discovery and synthesis of a novel antimicrobial peptide (RK22) from Hirudinaria manillensis salivary-gland transcriptome, followed by in-vitro and in-vivo antimicrobial assays against methicillin-resistant Staphylococcus aureus (MRSA); Kunming Institute of Zoology, Chinese Academy of Sciences
Method
Synthetic RK22 peptide administered against MRSA in-vitro (MIC determination, biofilm assays) and in-vivo (mouse model)
Main result
RK22 showed potent anti-MRSA activity (MIC 6.25 μg/mL) including clinically resistant strain; rapid bacterial killing; inhibited biofilm formation and promoted biofilm eradication; good plasma stability; negligible cytotoxicity; minimal hemolysis; no significant pro-coagulation effects; in-vivo administration significantly inhibited MRSA infection

Key Findings

  • Novel RK22 antimicrobial peptide identified from H. manillensis salivary gland transcriptome
  • Potent anti-MRSA activity (MIC 6.25 μg/mL) including clinically resistant strains
  • Biofilm inhibition and eradication — relevant to chronic-wound and indwelling-device infections
  • Good safety profile (low cytotoxicity, minimal hemolysis, no pro-coagulation)
  • In-vivo mouse efficacy demonstrated — supports advancing to GLP-toxicology and Phase-I evaluation

Limitations

  • Preclinical (in-vitro + mouse) — no human data
  • Mouse model does not capture all clinical complexity of MRSA disease
  • Long-term toxicology, pharmacokinetics, and immunogenicity not characterized
  • Resistance development potential not yet studied
  • Hirudinaria manillensis is not the K040187-cleared device leech

Clinical Implications

Lu 2023 illustrates how underrepresented Asian medicinal-leech sialotranscriptomes can yield translational antimicrobial drug candidates with activity against MDR pathogens. For ASH, the study underscores that leech-pharmacology is a deep biodiversity reservoir extending beyond the established hirudin literature. No US K040187 clinical-practice implications; relevant to translational antimicrobial drug discovery.

Related studies

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.